These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 36114370)
1. COVID 19, Paxlovid and the lesson from rare genetic diseases with naturally occurring protection from SARS-CoV-2 infection. Calò LA; Sgarabotto L; Stefanelli LF; Di Vico V; Davis PA J Nephrol; 2023 Apr; 36(3):925-927. PubMed ID: 36114370 [No Abstract] [Full Text] [Related]
2. Genetic Surveillance of SARS-CoV-2 M Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764 [TBL] [Abstract][Full Text] [Related]
3. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022. Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591 [TBL] [Abstract][Full Text] [Related]
4. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial. Xu J; Song J; Xie Z; Yang J; Wu D; Liu F; Zhao Y; Zang H; Zhao Y Medicine (Baltimore); 2023 Dec; 102(51):e36714. PubMed ID: 38134107 [TBL] [Abstract][Full Text] [Related]
5. A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients. Alteri C; Fox V; Scutari R; Burastero GJ; Volpi S; Faltoni M; Fini V; Granaglia A; Esperti S; Gallerani A; Costabile V; Fontana B; Franceschini E; Meschiari M; Campana A; Bernardi S; Villani A; Bernaschi P; Russo C; Guaraldi G; Mussini C; Perno CF Commun Biol; 2022 Dec; 5(1):1376. PubMed ID: 36522489 [TBL] [Abstract][Full Text] [Related]
6. SARS Chen M; Guo T; Zhou Z; Chen D; Zhou H Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 47(12):1775-1780. PubMed ID: 36748391 [TBL] [Abstract][Full Text] [Related]
7. Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS-COV-2 infection: A systematic review. Zhu CT; Yin JY; Chen XH; Liu M; Yang SG Rev Med Virol; 2023 Nov; 33(6):e2476. PubMed ID: 37578892 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial. Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813 [TBL] [Abstract][Full Text] [Related]
9. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients. Su P; Yang CX; Wang XG BMC Infect Dis; 2024 Jan; 24(1):44. PubMed ID: 38172735 [TBL] [Abstract][Full Text] [Related]
10. [COVID-19 treated with oral Nirmatrelvir-Ritonavir in 3 children]. Shi S; Dong N; Ding Y; Wang C; Yuan L; Fang YS; Wang BJ; Niu YH; Wei ZZ; Pu T; Dong XY; Lu Q Zhonghua Er Ke Za Zhi; 2022 Nov; 60(11):1168-1171. PubMed ID: 36319152 [No Abstract] [Full Text] [Related]
11. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987 [TBL] [Abstract][Full Text] [Related]
12. A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound. Ranard BL; Chow CC; Megjhani M; Asgari S; Park S; Vodovotz Y J Med Virol; 2023 Jun; 95(6):e28854. PubMed ID: 37287404 [TBL] [Abstract][Full Text] [Related]
13. Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection. Chen Y; Wan W; Yao X; Guan Y J Neuroimmunol; 2023 Dec; 385():578245. PubMed ID: 37992586 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Najjar-Debbiny R; Gronich N; Weber G; Khoury J; Amar M; Stein N; Goldstein LH; Saliba W Clin Infect Dis; 2023 Feb; 76(3):e342-e349. PubMed ID: 35653428 [TBL] [Abstract][Full Text] [Related]
15. Optimizing the use of Paxlovid in clinical practice. McCarthy MW Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515 [TBL] [Abstract][Full Text] [Related]
16. A naturally occurring G11S mutation in the 3C-like protease from the SARS-CoV-2 virus dramatically weakens the dimer interface. Wang G; Venegas FA; Rueda AM; Weerasinghe NW; Uggowitzer KA; Thibodeaux CJ; Moitessier N; Mittermaier AK Protein Sci; 2024 Jan; 33(1):e4857. PubMed ID: 38058248 [TBL] [Abstract][Full Text] [Related]
17. The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. Chen Q; Zhu K; Liu X; Zhuang C; Huang X; Huang Y; Yao X; Quan J; Lin H; Huang S; Su Y; Wu T; Zhang J; Xia N Emerg Microbes Infect; 2022 Dec; 11(1):793-803. PubMed ID: 35195494 [TBL] [Abstract][Full Text] [Related]
18. Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era. Niraj N; Mahajan SS; Prakash A; Sarma P; Medhi B Indian J Pharmacol; 2022; 54(6):452-458. PubMed ID: 36722557 [TBL] [Abstract][Full Text] [Related]
19. Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report. Zhang L; Zhang S; Han J; Yi Y; Zhou H; Li J Medicine (Baltimore); 2022 Nov; 101(45):e31361. PubMed ID: 36397388 [TBL] [Abstract][Full Text] [Related]
20. Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection. Sun F; Lin Y; Wang X; Gao Y; Ye S Lancet Infect Dis; 2022 Sep; 22(9):1279. PubMed ID: 35843259 [No Abstract] [Full Text] [Related] [Next] [New Search]